Sugi Predict

Sugi Predict / Compounds / SCHEMBL8544979

SCHEMBL8544979

SCHEMBL8544979

N#Cc1c(Cl)ncc(C=O)c1Cl

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 6/20 0.34
▸ MEN1 O00255 5/20 0.34
▸ HPGD P15428 2/20 0.34
▸ POLB P06746 1/20 0.34
▸ ALOX12 P18054 1/20 0.34
▸ MAPT P10636 4/20 0.32
▸ ALDH1A1 P00352 3/20 0.32
▸ MAPK1 P28482 3/20 0.32
▸ TP53 P04637 1/20 0.32
▸ CYP3A4 P08684 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ BCL6 P41182 3/20 0.32
▸ TDP1 Q9NUW8 2/20 0.31
▸ CHEK1 O14757 1/20 0.31
▸ AURKA O14965 1/20 0.31
▸ CDK2 P24941 1/20 0.31
▸ FLT4 P35916 1/20 0.31
▸ FLT3 P36888 1/20 0.31
▸ MAPKAPK2 P49137 1/20 0.31
▸ GSK3A P49840 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31111404 1.00 KMT2A (0.34) KMT2AMEN1HPGDPOLBALOX12
SCHEMBL8548916 0.76 ALDH1A1 (0.44) KMT2AMEN1ALDH1A1SMN1; SMN2TDP1
SCHEMBL19971159 0.76 ERN1 (0.33) KMT2AMEN1MAPTALDH1A1CYP3A4
SCHEMBL845675 0.74 — —
SCHEMBL846768 0.73 KDM4E (0.30) HPGDALDH1A1KDM4E
SCHEMBL846767 0.73 KDM4E (0.30) HPGDALDH1A1KDM4E
SCHEMBL8548155 0.72 ALDH1A1 (0.33) KMT2AMEN1MAPTALDH1A1CYP3A4
SCHEMBL8545018 0.72 ADORA1 (0.41) KMT2AMEN1HPGDPOLBMAPT
SCHEMBL15434050 0.71 CYP1A2 (0.38) KMT2AMEN1MAPTALDH1A1CYP3A4
SCHEMBL1413327 0.71 KMT2A (0.36) KMT2AMEN1HPGDPOLBALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250011338-A1 Kinase Inhibitors and Uses Thereof DENALI THERAPEUTICS INC. (US) 2025-01-09 — — US disclosed
US-12129263-B2 Kinase inhibitors and uses thereof DENALI THERAPEUTICS INC. (US) 2024-10-29 — — US disclosed
US-11530214-B2 Bicyclic heterocycles as FGFR inhibitors INCYTE HOLDINGS CORPORATION (US) 2022-12-20 — — US disclosed
US-11530214-B2 Bicyclic heterocycles as FGFR inhibitors INCYTE HOLDINGS CORPORATION (US) 2022-12-20 — — US disclosed
US-20220041620-A1 Kinase Inhibitors and Uses Thereof DENALI THERAPEUTICS INC. (US) 2022-02-10 — — US disclosed
CN-109776525-B Bicyclic heterocycles as FGFR inhibitors 因赛特控股公司 2022-01-21 — — CN disclosed
US-20210395246-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE HOLDINGS CORPORATION 2021-12-23 — — US disclosed
US-20210395246-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE HOLDINGS CORPORATION 2021-12-23 — — US disclosed
US-11203600-B2 Kinase inhibitors and uses thereof DENALI THERAPEUTICS INC. (US) 2021-12-21 — — US disclosed
EP-3318564-B1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE HOLDINGS CORP (US) 2021-07-28 — — EP disclosed
US-9533984-B2 Bicyclic heterocycles as FGFR inhibitors INCYTE HOLDINGS CORPORATION (US) 2017-01-03 — — US disclosed
EP-2986610-A2 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS Incyte Corporation (US) 2016-02-24 — — EP disclosed
WO-2014172644-A2 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION (US) 2014-10-23 — — WO disclosed
WO-2014172644-A2 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION (US) 2014-10-23 — — WO disclosed
US-20140315902-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION 2014-10-23 — — US disclosed
US-20140315902-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION 2014-10-23 — — US disclosed
US-20140315902-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION 2014-10-23 — — US disclosed
EP-0702003-B1 Process for preparing 2-halogenpyridinaldehydes BAYER AG (DE) 1998-06-17 — — EP disclosed
US-5708180-A CYCLIZATION OF UNSATURATED NITRILE, AMIDE OR OXIME BAYER AKTIENGESELLSCHAFT (DE) 1998-01-13 — — US disclosed
EP-0702003-A2 Process for preparing 2-halogenpyridinaldehydes and new 2-halogenpyridinaldehydes BAYER AG (DE) 1996-03-20 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210395246-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS FGFR1, FGFR3, FGFR2 KMT2A 926/4885MEN1 3227/4885HPGD 815/4885
US-20250011338-A1 Kinase Inhibitors and Uses Thereof MAP3K20, MAP3K6, MAP3K19 KMT2A 1686/4885MEN1 2281/4885HPGD 2930/4885
US-11530214-B2 Bicyclic heterocycles as FGFR inhibitors FGFR1, FGFR3, FGFR2 KMT2A 926/4885MEN1 3227/4885HPGD 815/4885
US-11203600-B2 Kinase inhibitors and uses thereof MAP3K20, MAP3K6, MAP3K19 KMT2A 1686/4885MEN1 2281/4885HPGD 2930/4885
US-20220041620-A1 Kinase Inhibitors and Uses Thereof MAP3K20, MAP3K6, MAP3K19 KMT2A 1686/4885MEN1 2281/4885HPGD 2930/4885
US-20140315902-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS FGFR1, FGFR3, FGFR2 KMT2A 926/4885MEN1 3227/4885HPGD 815/4885
US-12129263-B2 Kinase inhibitors and uses thereof MAP3K20, MAP3K6, MAP3K19 KMT2A 1686/4885MEN1 2281/4885HPGD 2930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.